跳至主要内容
临床试验/PACTR201807197019027
PACTR201807197019027已完成2 期

Safety and efficacy of different albendazole-based treatment regimens to reduce microfilaraemia in subjects infected by Loa loa in an endemic area of Gabon: a randomised controlled open-label pilot study

Ayola Akim Adegnika0 个研究点目标入组 42 人开始时间: 2018年6月7日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
42

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
19 Year(s) 至 44 Year(s)(—)
性别
Male

入选标准

  • Adult, male participants in the BuDiLoLo study
  • -L. loa microfilaria < 50,000 mf/mL
  • -Intention to remain residing in study area and comply with study procedures throughout 6 month follow-up period
  • -Signed written informed consent

排除标准

  • -Patients treated with albendazole during the 4 previous weeks
  • -Known intolerance or allergy to any study drug
  • -Viral hepatitis (HBV, HCV) or other known active liver disease
  • -HIV or other known immunosuppressive condition
  • -History of epilepsy, encephalitis, meningitis or encephalopathy
  • -Any other acute or chronic medical condition, medication or psychosocial factor(s) deemed by the Investigator to put the potential participant at greater than acceptable risk or to significantly affect study outcomes

研究者

发起方
Ayola Akim Adegnika

相似试验